The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Updated results from DREAMM-8: insights from a long-term responder analysis
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses updated results from the DREAMM-8 trial (NCT04484623) investigating belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in patients with relapsed/refractory (R/R) multiple myeloma (MM). He highlights that patients receiving BPd had higher rates of sustained measurable residual disease (MRD) negativity than those in the control arm, and outlines characteristics that resulted in a greater likelihood of achieving sustained MRD negative status. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
